A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

NCT00990821 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-Induced Nausea and Vomiting
Postoperative Nausea and Vomiting

Interventions

DRUG: 90 mg MK-0517 (PS80)
DRUG: 100 mg MK-0517 (PS80)
DRUG: 100 MK-0517 (PS80) + 2 mg midazolam
DRUG: 115 mg MK-0517 (PS80)
DRUG: 150 mg MK-0517 (PS80)
DRUG: 40 mg MK-0517 (non-PS80)
DRUG: 100 mg MK-0517 (non-PS80)
DRUG: 150 mg MK-0517 (Non-PS80)
DRUG: Placebo
DRUG: 40 mg Aprepitant
DRUG: 125 mg Aprepitant
DRUG: 2 mg Midazolam

Sponsor

Merck Sharp & Dohme LLC